Daewoong Pharm’s Nabota, the only home-grown Korean botulinum toxin approved and sold in the U.S., generated $13.2 million in sales in the third quarter, which is the first full quarter result of the neurotoxin after its launch in the U.S. in May.

The aesthetic botox product is marketed in the U.S. by the company’s local partner Evolus under the name of Jeuveau. Its May and June sales stood at $2.3 million in total.

During its third-quarter conference call on Monday, Evolus said the quarter ended September was focused on its Jeuveau experience treatment program or J.E.T. where over 5,000 accounts were enrolled and more than 10 vials per account were shipped.

Daewoong Pharm said an increasing volume of trial products through J.E.T. leads to a rapid conversion to order placement, and the penetration rate keeps growing among new consumers. Worldwide Nabota sales recognized on Daewoong Pharm’s end are also on the rise along with the product’s growing market share in the U.S. The company’s Nabota sales in the third quarter jumped 247 percent on year to 8.25 billion won ($7.12 million).

By Kim Byung-ho and Minu Kim

[ⓒ Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]